SILO Pharma (SILO Pharma) EBIT per Share : $-1.18 (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma EBIT per Share?

SILO Pharma's EBIT per Share for the three months ended in Mar. 2024 was $-0.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.18.

During the past 3 years, the average EBIT per Share Growth Rate was 6.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for SILO Pharma's EBIT per Share or its related term are showing as below:

SILO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.5 Med: -20.65 Max: 6.7
Current: 6.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of SILO Pharma was 6.70% per year. The lowest was -55.50% per year. And the median was -20.65% per year.

SILO's 3-Year EBIT Growth Rate is ranked better than
54.64% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs SILO: 6.70

SILO Pharma's EBIT for the three months ended in Mar. 2024 was $-0.80 Mil.

SILO Pharma EBIT per Share Historical Data

The historical data trend for SILO Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma EBIT per Share Chart

SILO Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.03

-1.82

2.18

-1.71

-1.18

SILO Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.29	-0.32	-0.21	-0.36	-0.28

SILO Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

SILO Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.626	/	3.080
=	-1.18

SILO Pharma's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.8	/	2.867
=	-0.28

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.18

SILO Pharma (NAS:SILO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

SILO Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of SILO Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SILO Pharma (SILO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632

Website

https://www.silopharma.com

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

Executives

Eric Weisblum	director, officer: President and CCO	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz	director	560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman	officer: Chief Financial Officer	1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller	director
Joel Alan Stone,	director	1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps	director	C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand	director, officer: Chairman and CEO	10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd	10 percent owner	P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats	officer: VP of Business Development	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis	director, officer: CFO	72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	72 POND ROAD, WOODBURY NY 11797